title: Anti-atherogenic effects of 17β-estradiol.
abstract: Estrogens are secreted primarily by the ovaries and placenta, by the testes in men and also produced by peripheral steroidogenic conversion. The 3 major naturally occurring estrogens are: 17β-estradiol (E2), estrone and estriol, of which E2 is the predominant and most active. The actions of E2 are mediated by at least 3 different receptors - the classical ERs (ERα and ERβ) and G-protein coupled receptor 30 (GPR30). E2 signaling in cardiomyocytes involves ERα- and ERβ-independent pathways, and treatment with the E2 receptor antagonists (Selective Estrogen Receptor Modulators- SERMs), which are agonists of GPR30, inhibits cardiac cell growth. Effects of E2 in preventing endothelial dysfunction, a prerequisite of atherosclerosis, are well recognized. Atherosclerosis involves interaction between the cells of the arterial wall endothelial cells (EC) and vascular smooth muscle cell (VSMC), as well as migration of macrophages into wall tunica media. It is predominantly developed at sites with abnormally high shear stress, such as bifurcations or branching of arteries, initiated by an injury to the endothelium and exposure to atherogenic lipids and toxins, such as those contained in tobacco smoke or infectious agents. Animal studies have shown effects of E2 in preventing atherosclerosis, inflammation and endothelial or vascular dysfunction. Gender differences along this pathogenic pathway have been also described. We review the data from the available animal and human studies, which focus on anti-atherogenic effects of E2. These studies represent evidence, albeit indirect, for an inhibitory effect of E2 on the progression of coronary artery atherosclerosis.
authors.affiliation: Laboratory of Radiobiology and Molecular Genetics, Institute Vinca, University of Belgrade, Belgrade, Serbia.
authors.forename: I
authors.initials: I
authors.lastname: Resanovic
authors.forename: M
authors.initials: M
authors.lastname: Rizzo
authors.forename: S
authors.initials: S
authors.lastname: Zafirovic
authors.forename: P
authors.initials: P
authors.lastname: Bjelogrlic
authors.forename: M
authors.initials: M
authors.lastname: Perovic
authors.forename: K
authors.initials: K
authors.lastname: Savic
authors.forename: A M
authors.initials: AM
authors.lastname: Patti
authors.forename: R E
authors.initials: RE
authors.lastname: Isenovic
mesh_terms: D000818:Animals; D050197:Atherosclerosis / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control*; D004036:Diet, Atherogenic / Q000009:adverse effects; D004958:Estradiol / Q000008:administration & dosage*; D015914:Estrogen Replacement Therapy / Q000706:statistics & numerical data; D005260:Female; D006801:Humans; D008297:Male; D010052:Ovariectomy / Q000009:adverse effects / Q000706:statistics & numerical data; D012307:Risk Factors; D020845:Selective Estrogen Receptor Modulators / Q000008:administration & dosage
chemical_list: D020845:Selective Estrogen Receptor Modulators; D004958:Estradiol